Sorafenib

🧮 Dose calculator

Hepatocellular carcinoma · Regimen source: FDA Nexavar · 2.1

• • Only under an oncologist; continue until progression or unacceptable toxicity. Dose adjustments for toxicity and interactions per label. FDA Nexavar · 2.1

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Nexavar · 8.1

  “Risk Summary Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology ( 12.1 )] , NEXAVAR may cause fetal harm when administered to a pregnant woman.”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Nexavar · 8.2

  “Because of the potential for serious adverse reactions in a breastfed child from NEXAVAR, advise women not to breastfeed during treatment with NEXAVAR and for 2 weeks after the last dose.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Nexavar · 8.4

  “The safety and effectiveness of NEXAVAR have not been established in pediatric patients.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Nexavar · 8.5

  “In total, 59% of HCC patients treated with NEXAVAR were age 65 years or older and 19% were 75 and older.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Nexavar · 8.3

  “Contraception Females Advise females of reproductive potential to use effective contraception during treatment and for 6 months following the last dose of NEXAVAR.”